Login to Your Account

Proteostasis off to races? CF drug pair could draw other players for buyout

By Randy Osborne
Staff Writer

Wednesday, August 31, 2016

Data due by the end of the year from the phase Ib trial testing Proteostasis Therapeutics Inc.'s CF prospect PTI-428 could trigger moves by developers in the space looking to pair the drug with therapies such as Orkambi from Vertex Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription